{"id":3828,"date":"2023-03-03T17:32:28","date_gmt":"2023-03-03T16:32:28","guid":{"rendered":"https:\/\/www.access2meds.eu\/consortium\/"},"modified":"2025-06-24T10:14:50","modified_gmt":"2025-06-24T08:14:50","slug":"consortium","status":"publish","type":"page","link":"https:\/\/www.access2meds.eu\/nl\/consortium\/","title":{"rendered":"Consortium"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.27.4″ _module_preset=”2e264158-b54d-4d7f-8146-8c8b7ca64cef” background_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1200929353_SolStock-e1679656039802.jpg” background_position=”top_center” background_last_edited=”on|phone” background_image_phone=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/06\/Mobile-Header-2.png” background_enable_image_phone=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” custom_padding=”7px|30px||30px|false|true” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” header_font=”|700||on|||||” header_text_color=”#E85D6B” header_font_size=”60px” custom_margin=”11px||||false|false” global_colors_info=”{}”]<\/p>\n

Consortium<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”first text colored pill” _builder_version=”4.20.0″ _module_preset=”default” background_enable_color=”off” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.2″ _module_preset=”default” vertical_offset=”-164px” custom_margin=”||-153px||false|false” custom_padding=”|0px||0px|false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” text_font_size=”20px” text_line_height=”1.33em” header_2_font=”Poppins regular||||||||” header_2_text_color=”#FFFFFF” header_2_font_size=”24px” background_color=”#048EA3″ max_width=”635px” module_alignment=”left” custom_padding=”60px|92px|60px|30px|true|false” custom_css_main_element=”overflow:visible;” custom_css_after=”content:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:635px;” border_radii=”off||999px|999px|” global_colors_info=”{}”]<\/p>\n

Dit hoofdstuk geeft een overzicht van het consortium van het ASCERTAIN-project, inclusief informatie over de projectpartners en hun respectievelijke rollen en verantwoordelijkheden.<\/p>\n

We zijn een consortium van partners uit zeven landen (Oostenrijk, Belgi\u00eb, Nederland, Slowakije, Noorwegen, Duitsland en Itali\u00eb) die samenwerken.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” custom_padding=”8px||36px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” custom_padding=”|30px|40px|30px|false|true” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/logo-erasmus-universiteit.png” title_text=”logo-erasmus-universiteit” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Erasmus Universiteit Rotterdam<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

De Erasmus Universiteit Rotterdam (EUR) is een universiteit in Rotterdam, Nederland, met 3.700 academische medewerkers en 23.867 studenten. De Erasmus School of Health Policy & Management (ESHPM) is een multidisciplinaire onderzoeks- en onderwijsschool aan de universiteit. Een van de afdelingen, het Institute for Medical Technology Assessment (iMTA), heeft een sleutelrol gespeeld in HTA-onderzoek in Nederland, Europa en wereldwijd. Het instituut heeft meer dan 600 onderzoeksprojecten uitgevoerd die werden gesponsord door belangrijke financiers zoals overheden en overheidsgerelateerde instellingen, de Europese Commissie, de WHO, gezondheidszorgorganisaties, liefdadigheidsstichtingen en de farmaceutische industrie. <\/p>\n

Rol in het project:<\/strong> EUR is de co\u00f6rdinator van dit project en brengt expertise in op het gebied van prijsstelling, gentherapie, celtherapie en vergoedingen.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/” button_text=”Bekijk team!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#fbedec” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}” custom_css_main_element_tablet=”width:20.65% !important;”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Comenius_University_Bratislava.svg” title_text=”Comenius_Universiteit_Bratislava” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_padding_phone=”|0px|20px||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}” custom_css_main_element_tablet=”width:79.35% !important;”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”0px||22px||false|false” global_colors_info=”{}”]<\/p>\n

Comenius University in Bratislava (UNIBA)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

De Comenius University in Bratislava is een onderzoeksinstelling die honderden nationale en internationale onderzoeksprojecten uitvoert. Een vertegenwoordiger van de farmaceutische faculteit van de Comenius Universiteit in Bratislava was namens het Zorgverzekeringsfonds van de Unie lid van het vergoedingscomit\u00e9 voor geneesmiddelen van het Slowaakse ministerie van Volksgezondheid. <\/p>\n

Rol in het project:<\/strong> UNIBA levert expertise op het gebied van medische hulpmiddelen en vergoedingen voor het project.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/” button_text=”Bekijk team!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ locked=”off” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#FFFFFF” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/06\/wortbildmarke-goeg-RGB.png” title_text=”wortbildmarke-goeg-RGB” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/” _builder_version=”4.25.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”200px” custom_margin=”5px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Gesundheit \u00d6sterreich GmbH (GOEG)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

The Austrian National Public Health Institute (Gesundheit \u00d6sterreich GmbH) is de instelling die verantwoordelijk is voor het onderzoek naar en de planning van de openbare gezondheidszorg in Oostenrijk. Het fungeert ook als nationaal competentie- en financieringscentrum voor gezondheidsbevordering en preventie en faciliteert onderzoek op het gebied van gezondheidszorg. GOEG is een openbare naamloze vennootschap zonder winstoogmerk die volledig in handen is van de Republiek Oostenrijk, vertegenwoordigd door het federale ministerie van Sociale Zaken, Gezondheid, Zorg en Consumentenbescherming. <\/p>\n

Rol in het project:<\/strong> GOEG levert expertise op het gebied van geneesmiddelenprijzen, prijs- en vergoedingsbeleid voor farmaceutische producten en medische hulpmiddelen en vergelijkend onderzoek naar farmaceutische systemen. Door haar samenwerking met beleidsmakers draagt GOEG ook bij aan informatie-uitwisseling en samenwerking tussen landen in het project. <\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/” button_text=”Bekijk team!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”rgba(57,60,132,0.15)” custom_padding=”45px||45px||true|false” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/university-of-oslo.png” title_text=”universiteit van-oslo” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_margin=”5px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Universitetet i Oslo <\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Universitet i Oslo is de grootste en oudste universiteit van Noorwegen. De universiteit heeft 27.700 studenten en 6.000 werknemers. De universiteit bestaat uit vijf faculteiten die onderzoek doen en onderwijs geven in theologie, rechten, geneeskunde, geesteswetenschappen, wiskunde en natuurwetenschappen, odontologie, sociale wetenschappen en sociale wetenschappen. De kernactiviteiten van de faculteit Geneeskunde zijn onderzoek, onderwijs, verspreiding en innovatie ten behoeve van pati\u00ebnten en de samenleving. <\/p>\n

Rol in het project:<\/strong> UIO draagt bij aan de use cases precisiegeneesmiddelen tegen kanker en medische hulpmiddelen, en met expertise in HTA, mathematische simulatiemodellering, prioriteitstelling en registergegevensanalyses.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/” button_text=”Bekijk team!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#FFFFFF” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/AIM-LOGO_png24.png” title_text=”AIM-LOGO_png24″ url=”https:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”150px” custom_margin=”5px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Association Internationale de la Mutualit\u00e9 (AIM)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

AIM fungeert als de internationale koepelorganisatie voor federaties van onderlinge zorgverzekeraars en wettelijke en aanvullende zorgverzekeringsorganen.
Het werk van de leden is gebaseerd op solidariteit, werken zonder winstoogmerk en democratie in heel Europa, Latijns-Amerika, Afrika en het Midden-Oosten.
AIM pleit voor gelijke toegang tot gezondheid en zorg, eerlijke prijzen van medicijnen, digitalisering ten dienste van de verzekerden, integratie van gezondheid in alle beleidsterreinen en meer aandacht voor preventie.<\/p>\n

Rol in het project:<\/strong> Het innovatieve algoritme dat betaalbaarheid en ondersteuning van waardevolle innovatie combineert, zal de basis vormen voor het innovatieve prijsmodel in ASCERTAIN.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/” button_text=”Bekijk team!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”rgba(133,184,189,0.3)” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/08\/Logo-EHA-Black.png” title_text=”Logo EHA – Zwart” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/” _builder_version=”4.27.0″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”150px” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

European Hematology Association <\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

European Hematology Association (EHA) – EHA is een niet-gouvernementele en non-profit ledenorganisatie die zich laat leiden door haar missie om uitmuntendheid in pati\u00ebntenzorg, onderzoek en onderwijs in de hematologie te bevorderen. EHA is de grootste in Europa gevestigde organisatie die medische professionals, onderzoekers en wetenschappers met interesse in hematologie samenbrengt. EHA vertegenwoordigt hematologie en hematologen in de Europese politieke en beleidsarena om de regelgeving te verbeteren, de beschikbaarheid en betaalbaarheid van geneesmiddelen te vergroten en de opleiding en training van hematologen te harmoniseren. <\/p>\n

Rol in het project:<\/strong> brengt expertise in op het gebied van prijsstelling en kosteneffectiviteit in het project.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/” button_text=”Bekijk team!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#FFFFFF” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Chino.io-logo.png” title_text=”Chino.io – logo” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Chino.io (CHINO)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Chino SRL is een Italiaans bedrijf voor cyberbeveiliging en cloudtechnologie dat in 2014 is opgericht met als missie ontwikkelaars van gezondheidstoepassingen te helpen bij het oplossen van problemen met de beveiliging en naleving van de privacywetgeving bij het omgaan met gezondheidsgevoelige gegevens in de cloud. Chino SRL heeft een softwareontwikkelingsplatform gecre\u00eberd met de naam Chino.io. Het platform biedt ontwikkelaars een set API’s om gevoelige gezondheidsgegevens veilig op te slaan, te delen en te beheren en volledig te voldoen aan alle wetten op het gebied van gegevensbescherming, waaronder GDPR, ePrivacy en HIPAA. <\/p>\n

Rol in het project:<\/strong> <\/span><\/strong>Gegevensbeheer & ethiek in WP2.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/” button_text=”Bekijk team!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#fbedec” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/MPE-Logo.png” title_text=”MPE-logo” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”100px” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Myeloma Patients Europe (MPE)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Myeloma Patients Europe (MPE) is een overkoepelende organisatie van myeloom en AL amylo\u00efdose pati\u00ebntengroepen in heel Europa. MPE heeft momenteel 53 leden in 33 landen. De missie van de organisatie is om onderwijs, informatie en ondersteuning te bieden aan ledengroepen en om op Europees, nationaal en lokaal niveau te pleiten voor het best mogelijke onderzoek en gelijke toegang tot behandeling en zorg. Om haar doelen te bereiken werkt de MPE rechtstreeks samen met leden, zorgverleners, vergoedingsautoriteiten, regelgevers, politici, farmaceutische bedrijven en de media om ervoor te zorgen dat alle belanghebbenden samenwerken om de resultaten voor pati\u00ebnten te verbeteren en ongelijkheden in heel Europa te verminderen. <\/p>\n

Rol in het project:<\/strong> pati\u00ebntenbetrokkenheid, identificeren van behoeften en voorkeuren van pati\u00ebnten voor de ontwikkeling van modellen.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/” button_text=”Bekijk team!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”RGBA(255,255,255,0)” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/OptiMedis_RGB.svg” title_text=”OptiMedis_RGB” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”130px” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

OptiMedis AG (OM)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

OptiMedis is een management- en gezondheidsgegevensanalysebedrijf geregistreerd in Duitsland. Haar kernactiviteit is het ontwikkelen en beheren van regionale ge\u00efntegreerde zorgsystemen met artsen netwerken en andere aanbieders. De aanpak van OptiMedis om gezondheidszorgsystemen te transformeren is veelvuldig erkend door de EU, meerdere EU-onderzoeksprojecten, het Commonwealth Fund, Duke Margolis Centre for Health Policy, de WHO, de Wereldbank en anderen. OptiMedis beheert drie ge\u00efntegreerde zorgsystemen in Duitsland met een populatie van meer dan 120.000 mensen en waarbij meer dan 150 zorgverleners betrokken zijn. OptiMedis is momenteel betrokken bij concurrerende onderzoeks- en implementatieprojecten met een volume van meer dan 10 miljoen euro. <\/p>\n

Rol in het project: <\/strong>Verspreiding en exploitatie van het project, groene productie van gezondheidstechnologie.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/” button_text=”Bekijk team!” button_alignment=”left” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_bg_color=”RGBA(255,255,255,0)” custom_padding_last_edited=”off|phone” button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”Contact” _builder_version=”4.20.2″ _module_preset=”default” background_color=”#86B8BD” custom_margin=”||||false|false” custom_padding=”16px||75px||false|false” box_shadow_style=”preset7″ box_shadow_horizontal=”0px” box_shadow_vertical=”-274px” box_shadow_color=”#FFFFFF” global_module=”910″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” header_font=”Poppins semibold|||on|||||” header_font_size=”36px” custom_margin=”14px||23px||false|false” custom_margin_tablet=”” custom_margin_phone=”||30px||false|false” custom_margin_last_edited=”on|phone” header_font_size_phone=”24px” global_colors_info=”{}”]<\/p>\n

Contact<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_font=”Poppins regular||||||||” text_text_color=”#393C84″ text_font_size=”24px” text_line_height=”1.33em” module_alignment=”right” custom_margin=”||0px||false|false” text_font_size_tablet=”” text_font_size_phone=”18px” text_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

Neem contact met ons op als je vragen of opmerkingen hebt! We nemen zo snel mogelijk contact met je op. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” module_class=”tablet-three-cols” _builder_version=”4.20.2″ _module_preset=”default” max_width_tablet=”980px” max_width_phone=”500px” max_width_last_edited=”on|phone” custom_padding=”0px|30px|0px|30px|false|true” global_colors_info=”{}” custom_css_main_element_last_edited=”on|phone” custom_css_main_element_tablet=”display:flex;” custom_css_main_element_phone=”display:flex; flex-direction:column;”][et_pb_column type=”1_3″ _builder_version=”4.20.2″ _module_preset=”be0fba28-f74a-4ba0-9a8d-9cd30aca805d” global_colors_info=”{}” custom_css_main_element_last_edited=”on|tablet” custom_css_main_element_tablet=”margin-bottom:0;” custom_css_main_element_phone=”margin-bottom:20px;”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Carin_Uyl-de-Groot.png” title_text=”Carin_Uyl-de-Groot” _builder_version=”4.20.2″ _module_preset=”a348f9e0-d57b-4c22-b522-c52b784fe57f” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” link_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

Voor onderzoeksgerelateerde vragen:<\/p>\n

Carin Uyl-de Groot<\/strong>
Projectco\u00f6rdinator<\/p>\n

Erasmus Universiteit Rotterdam
uyl@eshpm.eur.nl<\/a>
Telefoon: +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.20.2″ _module_preset=”be0fba28-f74a-4ba0-9a8d-9cd30aca805d” background_color=”#393C84″ global_colors_info=”{}” custom_css_main_element_last_edited=”on|phone” custom_css_main_element_tablet=”margin-bottom:0;” custom_css_main_element_phone=”margin-bottom:20px;”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Marcel-Langone-1.png” title_text=”Marcel-Langone” align=”center” _builder_version=”4.20.2″ _module_preset=”a348f9e0-d57b-4c22-b522-c52b784fe57f” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” link_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

Voor algemene projectvragen:<\/p>\n

Marcel Langone Marques<\/strong>
Projectmanager<\/p>\n

Erasmus Universiteit Rotterdam
marcel.langonemarques@eur.nl<\/a>
Telefoon: +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.20.2″ _module_preset=”be0fba28-f74a-4ba0-9a8d-9cd30aca805d” background_color=”#048EA3″ global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/06\/My-project-1-7.png” title_text=”Mijn project-1 (7)” _builder_version=”4.21.0″ _module_preset=”a348f9e0-d57b-4c22-b522-c52b784fe57f” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” link_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

Voor communicatie:<\/p>\n

Lena Jessen<\/strong>
Projectmanager<\/p>\n

OptiMedis
l.jessen@optimedis.de<\/a>
Telefoon: +49 40 226211490<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

ConsortiumDit hoofdstuk geeft een overzicht van het consortium van het ASCERTAIN-project, inclusief informatie over de projectpartners en hun respectievelijke rollen en verantwoordelijkheden. We zijn een consortium van partners uit zeven landen (Oostenrijk, Belgi\u00eb, Nederland, Slowakije, Noorwegen, Duitsland en Itali\u00eb) die samenwerken.Erasmus Universiteit RotterdamDe Erasmus Universiteit Rotterdam (EUR) is een universiteit in Rotterdam, Nederland, met 3.700 academische medewerkers en 23.867 studenten. De Erasmus School of Health Policy & Management (ESHPM) is een multidisciplinaire onderzoeks- en onderwijsschool aan de universiteit. Een van de afdelingen, het Institute for Medical Technology Assessment (iMTA), heeft een sleutelrol gespeeld in HTA-onderzoek in Nederland, Europa en wereldwijd. Het instituut heeft meer dan 600 onderzoeksprojecten uitgevoerd die werden gesponsord door belangrijke financiers zoals overheden en overheidsgerelateerde instellingen, de Europese Commissie, de WHO, gezondheidszorgorganisaties, liefdadigheidsstichtingen en de farmaceutische industrie. Rol in het project: EUR is de co\u00f6rdinator van dit project en brengt expertise in op het gebied van prijsstelling, gentherapie, celtherapie en vergoedingen.Comenius University in Bratislava (UNIBA)De Comenius University in Bratislava is een onderzoeksinstelling die honderden nationale en internationale onderzoeksprojecten uitvoert. Een vertegenwoordiger van de farmaceutische faculteit van de Comenius Universiteit in Bratislava was namens het Zorgverzekeringsfonds van de Unie lid van het vergoedingscomit\u00e9 voor geneesmiddelen van het Slowaakse […]<\/p>\n","protected":false},"author":1,"featured_media":3829,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-3828","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nConsortium - ASCERTAIN<\/title>\n<meta name=\"description\" content=\"Het ASCERTAIN-project brengt tien partners uit zeven landen samen - Oostenrijk, Belgi\u00eb, Nederland, Slowakije, Noorwegen, Duitsland en Itali\u00eb.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/nl\/consortium\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Consortium\" \/>\n<meta property=\"og:description\" content=\"Het ASCERTAIN-project brengt tien partners uit zeven landen samen - Oostenrijk, Belgi\u00eb, Nederland, Slowakije, Noorwegen, Duitsland en Itali\u00eb.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/nl\/consortium\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T08:14:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1254\" \/>\n\t<meta property=\"og:image:height\" content=\"836\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data1\" content=\"21 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/consortium\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/consortium\\\/\",\"name\":\"Consortium - ASCERTAIN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/consortium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/consortium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"datePublished\":\"2023-03-03T16:32:28+00:00\",\"dateModified\":\"2025-06-24T08:14:50+00:00\",\"description\":\"Het ASCERTAIN-project brengt tien partners uit zeven landen samen - Oostenrijk, Belgi\u00eb, Nederland, Slowakije, Noorwegen, Duitsland en Itali\u00eb.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/consortium\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/consortium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/consortium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"width\":1254,\"height\":836,\"caption\":\"10 partners from 7 different countries work together on ASCERTAIN\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/consortium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Consortium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Consortium - ASCERTAIN","description":"Het ASCERTAIN-project brengt tien partners uit zeven landen samen - Oostenrijk, Belgi\u00eb, Nederland, Slowakije, Noorwegen, Duitsland en Itali\u00eb.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/nl\/consortium\/","og_locale":"nl_NL","og_type":"article","og_title":"Consortium","og_description":"Het ASCERTAIN-project brengt tien partners uit zeven landen samen - Oostenrijk, Belgi\u00eb, Nederland, Slowakije, Noorwegen, Duitsland en Itali\u00eb.","og_url":"https:\/\/www.access2meds.eu\/nl\/consortium\/","og_site_name":"ASCERTAIN","article_modified_time":"2025-06-24T08:14:50+00:00","og_image":[{"width":1254,"height":836,"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Geschatte leestijd":"21 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/nl\/consortium\/","url":"https:\/\/www.access2meds.eu\/nl\/consortium\/","name":"Consortium - ASCERTAIN","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/nl\/consortium\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/nl\/consortium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","datePublished":"2023-03-03T16:32:28+00:00","dateModified":"2025-06-24T08:14:50+00:00","description":"Het ASCERTAIN-project brengt tien partners uit zeven landen samen - Oostenrijk, Belgi\u00eb, Nederland, Slowakije, Noorwegen, Duitsland en Itali\u00eb.","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/nl\/consortium\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/nl\/consortium\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.access2meds.eu\/nl\/consortium\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","width":1254,"height":836,"caption":"10 partners from 7 different countries work together on ASCERTAIN"},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/nl\/consortium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/nl\/startpagina\/"},{"@type":"ListItem","position":2,"name":"Consortium"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/pages\/3828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/comments?post=3828"}],"version-history":[{"count":13,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/pages\/3828\/revisions"}],"predecessor-version":[{"id":4527,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/pages\/3828\/revisions\/4527"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/media\/3829"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/media?parent=3828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}